Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells

Cancer Science

Volumn 100, Issue 10, 2009, Pages 1963-1970

  Ohga, Noritaka ^a,b   Hida, Kyoko ^a,b   Hida, Yasuhiro ^c   Muraki, Chikara ^a,b   Tsuchiya, Kunihiko ^d   Matsuda, Kohei ^a,b   Ohiro, Yoichi ^b   Totsuka, Yasunori ^b   Shindoh, Masanobu ^a  

^a Department of Oral Biochemistry and Molecular Biology   (Japan)

^b Graduate School of Dental Medicine   (Japan)

^c Graduate School of Science   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIGALLOCATECHIN GALLATE; GELATINASE B; MESSENGER RNA; POLYPHENOL; PROTEIN KINASE B; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER CELL; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MICROVASCULATURE; MOUSE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STEM CELL; STEM CELL MOBILIZATION; STROMA CELL; TEA;

ANIMALS; ANTICARCINOGENIC AGENTS; BLOTTING, WESTERN; CATECHIN; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; ENDOTHELIAL CELLS; FLAVONOIDS; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; MATRIX METALLOPROTEINASE 9; MELANOMA; MICE; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; PHENOLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEM CELLS; TEA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349609377     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01255.x     Document Type: Article

References (50)

1. Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst 1993, 85:1038-49.
2. Wang ZY, Wang LD, Lee MJ. Inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in rats by green and black tea. Carcinogenesis 1995, 16:2143-8.
3. Yang CS, Chung JY, Yang G, Chhabra SK, Lee MJ. Tea and tea polyphenols in cancer prevention. J Nutr 2000, 130:472S-8S.
4. Fujiki H, Suganuma M, Imai K, Nakachi K. Green tea: cancer preventive beverage and/or drug. Cancer Lett 2002, 188:9-13.
5. Mukhtar H, Katiyar SK, Agarwal R. Cancer chemoprevention by green tea components. Adv Exp Med Biol 1994, 354:123-34.
6. Mukhtar H, Katiyar SK, Agarwal R. Green tea and skin - anticarcinogenic effects. J Invest Dermatol 1994, 102:3-7.
7. Jankun J, Selman SH, Swiercz R, Skrzypczak-Jankun E. Why drinking green tea could prevent cancer. Nature 1997, 387:561.
8. Cao Y, Cao R, Brakenhielm E. Antiangiogenic mechanisms of diet-derived polyphenols. J Nutr Biochem 2002, 13:380-90.
9. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007, 7:139-47.
10. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006, 312:1171-5.
11. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001, 106:148-56.
12. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001, 280:C1358-66.
13. Fassina G, Vene R, Morini M. Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res 2004, 10:4865-73.
14. Kondo T, Ohta T, Igura K, Hara Y, Kaji K. Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding. Cancer Lett 2002, 180:139-44.
15. Lamy S, Gingras D, Beliveau R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res 2002, 62:381-5.
16. Tang FY, Meydani M. Green tea catechins and vitamin E inhibit angiogenesis of human microvascular endothelial cells through suppression of IL-8 production. Nutr Cancer 2001, 41:119-25.
17. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-6.
18. Allinen M, Beroukhim R, Cai L. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
19. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003, 9:713-25.
20. St Croix B, Rago C, Velculescu V. Genes expressed in human tumor endothelium. Science 2000, 289:1197-202.
21. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002, 160:985-1000.
22. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. Faseb J 2003, 17:1159-61.
23. Hida K, Hida Y, Amin DN. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004, 64:8249-55.
24. Hida K, Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 2005, 65:2507-10.
25. Amin DN, Hida K, Bielenberg DR, Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 2006, 66:2173-80.
26. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat Rev Cancer 2002, 2:826-35.
27. Heissig B, Werb Z, Rafii S, Hattori K. Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb Haemost 2003, 90:570-6.
28. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006, 6:835-45.
29. Nolan DJ, Ciarrocchi A, Mellick AS. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 2007, 21:1546-58.
30. Cheng XW, Kuzuya M, Nakamura K. Mechanisms underlying the impairment of ischemia-induced neovascularization in matrix metalloproteinase 2-deficient mice. Circ Res 2007, 100:904-13.
31. Arbiser JL, Raab G, Rohan RM. Isolation of mouse stromal cells associated with a human tumor using differential diphtheria toxin sensitivity. Am J Pathol 1999, 155:723-9.
32. Beaudry P, Hida Y, Udagawa T. Endothelial progenitor cells contribute to accelerated liver regeneration. J Pediatr Surg 2007, 42:1190-8.
33. Dormond O, Foletti A, Paroz C, Ruegg C. NSAIDs inhibit αVβ;3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 2001, 7:1041-7.
34. Bielenberg DR, Hida Y, Shimizu A. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 2004, 114:1260-71.
35. Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WM. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 2006, 169:1875-85.
36. Asahara T, Murohara T, Sullivan A. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-7.
37. Asahara T, Takahashi T, Masuda H. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999, 18:3964-72.
38. Sharpe EE 3rd, Teleron AA, Li B. The origin and in vivo significance of murine and human culture-expanded endothelial progenitor cells. Am J Pathol 2006, 168:1710-21.
39. Ramanadham S, Yarasheski KE, Silva MJ. Age-related changes in bone morphology are accelerated in group VIA phospholipase A2 (iPLA2beta)-null mice. Am J Pathol 2008, 172:868-81.
40. Bussolati B, Assenzio B, Deregibus MC, Camussi G. The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. J Mol Med 2006, 84:852-63.
41. Rodriguez SK, Guo W, Liu L, Band MA, Paulson EK, Meydani M. Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int J Cancer 2006, 118:1635-44.
42. Gerber HP, McMurtrey A, Kowalski J. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998, 273:30 336-43.
43. Dimmeler S, Hermann C, Zeiher AM. Apoptosis of endothelial cells. Contribution to the pathophysiology of atherosclerosis?. Eur Cytokine Netw 1998, 9:697-8.
44. Dimmeler S, Dernbach E, Zeiher AM. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett 2000, 477:258-62.
45. Morales-Ruiz M, Fulton D, Sowa G. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ Res 2000, 86:892-6.
46. Hida K, Hida Y, Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 2008, 99:459-66.
47. Lyden D, Hattori K, Dias S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7:1194-201.
48. Shaked Y, Bertolini F, Man S. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005, 7:101-11.
49. Gehling UM, Ergun S, Schumacher U. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000, 95:3106-12.
50. Siddiqui IA, Malik A, Adhami VM. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2007, 27:2055-63.